{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,11]],"date-time":"2026-06-11T16:38:33Z","timestamp":1781195913458,"version":"3.54.1"},"reference-count":43,"publisher":"Elsevier BV","issue":"5","license":[{"start":{"date-parts":[[2024,5,1]],"date-time":"2024-05-01T00:00:00Z","timestamp":1714521600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,5,1]],"date-time":"2024-05-01T00:00:00Z","timestamp":1714521600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/501100001659","name":"Deutsche Forschungsgemeinschaft","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100001659","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.fr","clinicalkey.jp","clinicalkey.es","clinicalkey.com.au","ajkd.org","clinicalkey.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["American Journal of Kidney Diseases"],"published-print":{"date-parts":[[2024,5]]},"DOI":"10.1053\/j.ajkd.2023.10.013","type":"journal-article","created":{"date-parts":[[2023,12,25]],"date-time":"2023-12-25T06:30:20Z","timestamp":1703485820000},"page":"588-600.e1","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":13,"title":["Anti\u2013Phospholipase A2 Receptor 1 and Anti\u2013Cysteine Rich Antibodies, Domain Recognition and Rituximab Efficacy in Membranous Nephropathy: A Prospective Cohort Study"],"prefix":"10.1053","volume":"83","author":[{"given":"Piero","family":"Ruggenenti","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Linda","family":"Reinhard","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Barbara","family":"Ruggiero","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Annalisa","family":"Perna","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luca","family":"Perico","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tobia","family":"Peracchi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Diego","family":"Fidone","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alessia","family":"Gennarini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ariela","family":"Benigni","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Monica","family":"Cortinovis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elion","family":"Hoxha","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giuseppe","family":"Remuzzi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"5","key":"10.1053\/j.ajkd.2023.10.013_bib1","doi-asserted-by":"crossref","first-page":"621","DOI":"10.1016\/S0272-6386(97)90485-6","article-title":"Changing etiologies of unexplained adult nephrotic syndrome: a comparison of renal biopsy findings from 1976-1979 and 1995-1997","volume":"30","author":"Haas","year":"1997","journal-title":"Am J Kidney Dis"},{"issue":"9","key":"10.1053\/j.ajkd.2023.10.013_bib2","doi-asserted-by":"crossref","first-page":"563","DOI":"10.1038\/nrneph.2017.92","article-title":"Treatment of membranous nephropathy: time for a paradigm shift","volume":"13","author":"Ruggenenti","year":"2017","journal-title":"Nat Rev Nephrol"},{"issue":"7","key":"10.1053\/j.ajkd.2023.10.013_bib3","doi-asserted-by":"crossref","first-page":"466","DOI":"10.1038\/s41581-022-00564-1","article-title":"Membranous nephropathy: new pathogenic mechanisms and their clinical implications","volume":"18","author":"Hoxha","year":"2022","journal-title":"Nat Rev Nephrol"},{"issue":"1","key":"10.1053\/j.ajkd.2023.10.013_bib4","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1056\/NEJMoa0810457","article-title":"M-type phospholipase A2 receptor as target antigen in idiopathic membranous nephropathy","volume":"361","author":"Beck","year":"2009","journal-title":"N\u00a0Engl J Med"},{"issue":"2","key":"10.1053\/j.ajkd.2023.10.013_bib5","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1056\/NEJM199307083290203","article-title":"Prognosis of untreated patients with idiopathic membranous nephropathy","volume":"329","author":"Schieppati","year":"1993","journal-title":"N\u00a0Engl J Med"},{"issue":"4","key":"10.1053\/j.ajkd.2023.10.013_bib6","doi-asserted-by":"crossref","first-page":"960","DOI":"10.1038\/ki.1992.374","article-title":"Predicting chronic renal insufficiency in idiopathic membranous glomerulonephritis","volume":"42","author":"Pei","year":"1992","journal-title":"Kidney Int"},{"issue":"3","key":"10.1053\/j.ajkd.2023.10.013_bib7","doi-asserted-by":"crossref","first-page":"995","DOI":"10.1681\/ASN.2015111262","article-title":"Membranous nephropathy: quantifying remission duration on outcome","volume":"28","author":"Cattran","year":"2017","journal-title":"J\u00a0Am Soc Nephrol"},{"issue":"10","key":"10.1053\/j.ajkd.2023.10.013_bib8","doi-asserted-by":"crossref","first-page":"2545","DOI":"10.1681\/ASN.2014070640","article-title":"Anti-phospholipase A2 receptor antibody titer predicts post-rituximab outcome of membranous nephropathy","volume":"26","author":"Ruggenenti","year":"2015","journal-title":"J\u00a0Am Soc Nephrol"},{"issue":"5","key":"10.1053\/j.ajkd.2023.10.013_bib9","doi-asserted-by":"crossref","first-page":"940","DOI":"10.1038\/ki.2012.486","article-title":"Anti-PLA2R antibodies measured by ELISA predict long-term outcome in a prevalent population of patients with idiopathic membranous nephropathy","volume":"83","author":"Kanigicherla","year":"2013","journal-title":"Kidney Int"},{"issue":"8","key":"10.1053\/j.ajkd.2023.10.013_bib10","doi-asserted-by":"crossref","first-page":"1386","DOI":"10.2215\/CJN.10471013","article-title":"Association of anti-PLA2R antibodies with outcomes after immunosuppressive therapy in idiopathic membranous nephropathy","volume":"9","author":"Bech","year":"2014","journal-title":"Clin J Am Soc Nephrol"},{"issue":"6","key":"10.1053\/j.ajkd.2023.10.013_bib11","doi-asserted-by":"crossref","first-page":"1357","DOI":"10.1681\/ASN.2013040430","article-title":"Phospholipase A2 receptor autoantibodies and clinical outcome in patients with primary membranous nephropathy","volume":"25","author":"Hoxha","year":"2014","journal-title":"J\u00a0Am Soc Nephrol"},{"issue":"5","key":"10.1053\/j.ajkd.2023.10.013_bib12","doi-asserted-by":"crossref","first-page":"1517","DOI":"10.1681\/ASN.2014111061","article-title":"Epitope spreading of autoantibody response to PLA2R associates with poor prognosis in membranous nephropathy","volume":"27","author":"Seitz-Polski","year":"2016","journal-title":"J\u00a0Am Soc Nephrol"},{"issue":"15","key":"10.1053\/j.ajkd.2023.10.013_bib13","doi-asserted-by":"crossref","first-page":"8963","DOI":"10.1074\/jbc.270.15.8963","article-title":"The human 180-kDa receptor for secretory phospholipases A2: molecular cloning, identification of a secreted soluble form, expression, and chromosomal localization","volume":"270","author":"Ancian","year":"1995","journal-title":"J\u00a0Biol Chem"},{"issue":"2","key":"10.1053\/j.ajkd.2023.10.013_bib14","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1681\/ASN.2013121315","article-title":"Identification of the immunodominant epitope region in phospholipase A2 receptor-mediating autoantibody binding in idiopathic membranous nephropathy","volume":"26","author":"Kao","year":"2015","journal-title":"J\u00a0Am Soc Nephrol"},{"issue":"2","key":"10.1053\/j.ajkd.2023.10.013_bib15","first-page":"401","article-title":"Phospholipase A2\u00a0receptor 1 epitope spreading at baseline predicts reduced likelihood of remission of membranous nephropathy","volume":"29","author":"Seitz-Polski","year":"2018","journal-title":"J\u00a0Am\u00a0Soc\u00a0Nephrol"},{"issue":"1","key":"10.1053\/j.ajkd.2023.10.013_bib16","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1681\/ASN.2019030273","article-title":"Clinical relevance of domain-specific phospholipase A2 receptor 1 antibody levels in patients with membranous nephropathy","volume":"31","author":"Reinhard","year":"2020","journal-title":"J\u00a0Am Soc Nephrol"},{"issue":"2","key":"10.1053\/j.ajkd.2023.10.013_bib17","doi-asserted-by":"crossref","first-page":"302","DOI":"10.1681\/ASN.2014050502","article-title":"Identification of a major epitope recognized by PLA2R autoantibodies in primary membranous nephropathy","volume":"26","author":"Fresquet","year":"2015","journal-title":"J\u00a0Am Soc Nephrol"},{"issue":"4","key":"10.1053\/j.ajkd.2023.10.013_bib18","doi-asserted-by":"crossref","first-page":"753","DOI":"10.1016\/j.kint.2021.05.015","article-title":"Executive summary of the KDIGO 2021 guideline for the management of glomerular diseases","volume":"100","author":"Rovin","year":"2021","journal-title":"Kidney Int"},{"issue":"5","key":"10.1053\/j.ajkd.2023.10.013_bib19","doi-asserted-by":"crossref","first-page":"932","DOI":"10.2215\/CJN.01180307","article-title":"Titrating rituximab to circulating B cells to optimize lymphocytolytic therapy in idiopathic membranous nephropathy","volume":"2","author":"Cravedi","year":"2007","journal-title":"Clin J Am Soc Nephrol"},{"key":"10.1053\/j.ajkd.2023.10.013_bib21","doi-asserted-by":"crossref","DOI":"10.3389\/fphar.2022.958136","article-title":"Sexual dimorphic response to rituximab treatment: a longitudinal observational study in a large cohort of patients with primary membranous nephropathy and persistent nephrotic syndrome","volume":"13","author":"Perna","year":"2022","journal-title":"Front Pharmacol"},{"issue":"8","key":"10.1053\/j.ajkd.2023.10.013_bib22","doi-asserted-by":"crossref","first-page":"1416","DOI":"10.1681\/ASN.2012020181","article-title":"Rituximab in idiopathic membranous nephropathy","volume":"23","author":"Ruggenenti","year":"2012","journal-title":"J\u00a0Am Soc Nephrol"},{"key":"10.1053\/j.ajkd.2023.10.013_bib23","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1016\/j.cca.2013.03.015","article-title":"Development of a standardized ELISA for the determination of autoantibodies against human M-type phospholipase A2 receptor in primary membranous nephropathy","volume":"421","author":"Dahnrich","year":"2013","journal-title":"Clin Chim Acta"},{"issue":"12","key":"10.1053\/j.ajkd.2023.10.013_bib24","doi-asserted-by":"crossref","first-page":"1503","DOI":"10.1016\/0895-4356(95)00048-8","article-title":"Importance of events per independent variable in proportional hazards regression analysis. II. Accuracy and precision of regression estimates","volume":"48","author":"Peduzzi","year":"1995","journal-title":"J\u00a0Clin Epidemiol"},{"issue":"9981","key":"10.1053\/j.ajkd.2023.10.013_bib25","doi-asserted-by":"crossref","first-page":"1983","DOI":"10.1016\/S0140-6736(15)60731-0","article-title":"Pathophysiological advances in membranous nephropathy: time for a shift in patient\u2019s care","volume":"385","author":"Ronco","year":"2015","journal-title":"Lancet"},{"issue":"1","key":"10.1053\/j.ajkd.2023.10.013_bib26","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1053\/ajkd.1998.v31.pm9428445","article-title":"Prognostic factors in idiopathic membranous nephropathy","volume":"31","author":"Reichert","year":"1998","journal-title":"Am J Kidney Dis"},{"issue":"4","key":"10.1053\/j.ajkd.2023.10.013_bib27","doi-asserted-by":"crossref","first-page":"324","DOI":"10.1016\/S0270-9295(03)00049-4","article-title":"Diagnosis and natural course of membranous nephropathy","volume":"23","author":"Glassock","year":"2003","journal-title":"Semin Nephrol"},{"issue":"7","key":"10.1053\/j.ajkd.2023.10.013_bib28","doi-asserted-by":"crossref","first-page":"2247","DOI":"10.1093\/ndt\/gfm919","article-title":"The impact of sex in primary glomerulonephritis","volume":"23","author":"Cattran","year":"2008","journal-title":"Nephrol Dial Transplant"},{"issue":"4","key":"10.1053\/j.ajkd.2023.10.013_bib29","doi-asserted-by":"crossref","first-page":"1484","DOI":"10.1046\/j.1523-1755.2001.0590041484.x","article-title":"Cyclosporine in patients with steroid-resistant membranous nephropathy: a randomized trial","volume":"59","author":"Cattran","year":"2001","journal-title":"Kidney Int"},{"issue":"9","key":"10.1053\/j.ajkd.2023.10.013_bib30","doi-asserted-by":"crossref","first-page":"924","DOI":"10.1038\/sj.ki.5002215","article-title":"Tacrolimus monotherapy in membranous nephropathy: a randomized controlled trial","volume":"71","author":"Praga","year":"2007","journal-title":"Kidney Int"},{"issue":"8","key":"10.1053\/j.ajkd.2023.10.013_bib31","doi-asserted-by":"crossref","first-page":"443","DOI":"10.1038\/nrneph.2013.125","article-title":"Treatment of idiopathic membranous nephropathy","volume":"9","author":"Hofstra","year":"2013","journal-title":"Nat Rev Nephrol"},{"issue":"8","key":"10.1053\/j.ajkd.2023.10.013_bib32","doi-asserted-by":"crossref","first-page":"762","DOI":"10.1111\/j.1440-1797.2010.01301.x","article-title":"Benefit and cost from the long-term use of cyclosporine-A in idiopathic membranous nephropathy","volume":"15","author":"Kalliakmani","year":"2010","journal-title":"Nephrology (Carlton)"},{"issue":"3","key":"10.1053\/j.ajkd.2023.10.013_bib33","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1159\/000430849","article-title":"A\u00a0multicenter randomized controlled trial of rituximab versus cyclosporine in the treatment of idiopathic membranous nephropathy (MENTOR)","volume":"130","author":"Fervenza","year":"2015","journal-title":"Nephron"},{"issue":"1","key":"10.1053\/j.ajkd.2023.10.013_bib34","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1084\/jem.182.1.75","article-title":"Functional evidence for epitope spreading in the relapsing pathology of experimental autoimmune encephalomyelitis","volume":"182","author":"McRae","year":"1995","journal-title":"J\u00a0Exp Med"},{"issue":"11","key":"10.1053\/j.ajkd.2023.10.013_bib35","doi-asserted-by":"crossref","first-page":"1501","DOI":"10.1084\/jem.20022031","article-title":"The role of intramolecular epitope spreading in the pathogenesis of endemic pemphigus foliaceus (fogo selvagem)","volume":"197","author":"Li","year":"2003","journal-title":"J\u00a0Exp Med"},{"issue":"1","key":"10.1053\/j.ajkd.2023.10.013_bib36","doi-asserted-by":"crossref","first-page":"51","DOI":"10.2215\/CJN.05140512","article-title":"Association of epitope spreading of antiglomerular basement membrane antibodies and kidney injury","volume":"8","author":"Chen","year":"2013","journal-title":"Clin J Am Soc Nephrol"},{"issue":"12","key":"10.1053\/j.ajkd.2023.10.013_bib37","doi-asserted-by":"crossref","first-page":"3060","DOI":"10.1681\/ASN.2007030342","article-title":"Intramolecular epitope spreading in Heymann nephritis","volume":"18","author":"Shah","year":"2007","journal-title":"J\u00a0Am Soc Nephrol"},{"issue":"1","key":"10.1053\/j.ajkd.2023.10.013_bib38","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1016\/j.imlet.2014.11.001","article-title":"B\u00a0cell epitope spreading: mechanisms and contribution to autoimmune diseases","volume":"163","author":"Cornaby","year":"2015","journal-title":"Immunol Lett"},{"issue":"1","key":"10.1053\/j.ajkd.2023.10.013_bib39","doi-asserted-by":"crossref","first-page":"208","DOI":"10.1681\/ASN.2019050538","article-title":"Detection of PLA2R autoantibodies before the diagnosis of membranous nephropathy","volume":"31","author":"Burbelo","year":"2020","journal-title":"J\u00a0Am Soc Nephrol"},{"issue":"8","key":"10.1053\/j.ajkd.2023.10.013_bib40","doi-asserted-by":"crossref","first-page":"594","DOI":"10.1038\/nri2815","article-title":"The X chromosome in immune functions: when a chromosome makes the difference","volume":"10","author":"Libert","year":"2010","journal-title":"Nat Rev Immunol"},{"issue":"1","key":"10.1053\/j.ajkd.2023.10.013_bib41","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1016\/j.kint.2017.01.012","article-title":"B- and T-cell subpopulations in patients with severe idiopathic membranous nephropathy may predict an early response to rituximab","volume":"92","author":"Rosenzwajg","year":"2017","journal-title":"Kidney Int"},{"issue":"2","key":"10.1053\/j.ajkd.2023.10.013_bib42","doi-asserted-by":"crossref","first-page":"182","DOI":"10.1016\/j.ekir.2019.11.008","article-title":"Development of a standardized chemiluminescence immunoassay for the detection of autoantibodies against human M-type phospholipase A2 receptor in primary membranous nephropathy","volume":"5","author":"D\u00e4hnrich","year":"2020","journal-title":"Kidney Int Rep"},{"issue":"5","key":"10.1053\/j.ajkd.2023.10.013_bib43","doi-asserted-by":"crossref","first-page":"461","DOI":"10.1159\/000327611","article-title":"Efficacy and safety of rituximab second-line therapy for membranous nephropathy: a prospective, matched-cohort study","volume":"33","author":"Cravedi","year":"2011","journal-title":"Am J Nephrol"},{"issue":"2","key":"10.1053\/j.ajkd.2023.10.013_bib44","doi-asserted-by":"crossref","first-page":"421","DOI":"10.1681\/ASN.2016070776","article-title":"A\u00a0proposal for a serology-based approach to membranous nephropathy","volume":"28","author":"De Vriese","year":"2017","journal-title":"J\u00a0Am Soc Nephrol"}],"container-title":["American Journal of Kidney Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0272638623009939?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0272638623009939?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,10,17]],"date-time":"2024-10-17T05:01:55Z","timestamp":1729141315000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0272638623009939"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,5]]},"references-count":43,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2024,5]]}},"alternative-id":["S0272638623009939"],"URL":"https:\/\/doi.org\/10.1053\/j.ajkd.2023.10.013","relation":{},"ISSN":["0272-6386"],"issn-type":[{"value":"0272-6386","type":"print"}],"subject":[],"published":{"date-parts":[[2024,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Anti\u2013Phospholipase A2 Receptor 1 and Anti\u2013Cysteine Rich Antibodies, Domain Recognition and Rituximab Efficacy in Membranous Nephropathy: A Prospective Cohort Study","name":"articletitle","label":"Article Title"},{"value":"American Journal of Kidney Diseases","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1053\/j.ajkd.2023.10.013","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 by the National Kidney Foundation, Inc.","name":"copyright","label":"Copyright"}]}}